Greg Sieczkiewicz, J.D., Ph.D.
Executive Partner & Chief IP Counsel
Dr. Greg Sieczkiewicz serves as Chief IP Counsel for several MPM portfolio companies including iTeos Therapeutics, TCR² Therapeutics, Trieza Therapeutics and Werewolf Therapeutics.
Prior to joining MPM, Greg was the IP strategy architect for more than a dozen venture-backed life sciences companies across the spectrum—from nucleic acid therapeutics, oral biologics and the microbiome to oncology and protein engineering. He has served as Vice President, IP at Flagship Ventures, and also practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association.
Greg received his J.D., magna cum laude, from the evening program of Suffolk University Law School and earned his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and completed his post-doctoral fellowship at the National Cancer Institute. He received his A.B. in Biology from the College of the Holy Cross.